Regeneron Deal Pushes Tessera Into Its Next Chapter

Tessera Therapeutics is stepping into a defining moment in its evolution. The company has secured a $275 million partnership with RegeneronDealroom has a profile for this one. Try Dealroom →, giving its novel gene-editing platform the backing of one of the most influential players in genetic medicine. For Tessera, this isn’t just a deal — it’s the bridge from years of platform development to its first potential clinical program.

The spotlight is on TSRA-196 , Tessera’s lead in vivo gene editor. Designed to precisely correct the SERPINA1 mutation that causes alpha-1 antitrypsin deficiency (AATD), the therapy aims to restore normal protein production with a single treatment. Preclinical results have strengthened confidence in the technology: high editing efficiency in non-human primates, rare off-target effects, and no detectable germline edits. For Tessera, these data represent a proof point that its “writing” approach to gene editing could offer durable solutions where traditional methods fall short.

Regeneron’s commitment underscores that potential. The company is providing $150 million upfront — a combination of cash and equity — with another $125 million available through near- and mid-term milestones. Under the agreement, Tessera will lead the first-in-human trial, expected to begin after an IND submission later this year, before Regeneron assumes responsibility for broader global development. The two will share costs and profits equally.

For Tessera, this partnership marks its transition from an ambitious platform company to a clinical-stage contender. With Regeneron supporting its debut program, Tessera now has both the resources and the validation needed to bring its technology into patients for the first time. If TSRA-196 delivers on its promise, it could reshape the landscape for in vivo gene editing — and establish Tessera as one of the field’s defining companies.

Source:
Bio Space

A.M.